Myocardial Infarction News and Research

RSS

Tailored anti-clotting medications reduce adverse effects after percutaneous coronary intervention

Individually tailored anti-clotting medication dosing significantly cut the rate of adverse events after non-emergent percutaneous coronary intervention (PCI) with stenting, researchers reported at the American Heart Association's Scientific Sessions 2008. Results of the Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Stent Thrombosis study were presented as a late-breaking clinical trial.

11 Nov 2008

Timing is everything for some heart attack patients

There is strong evidence that getting to the hospital quickly during a heart attack is critical, since early treatment saves both lives and heart muscle. And if the responsible coronary artery is completely blocked, it should be opened as soon as possible.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Public smoking ban would reduce heart attack admissions

The number of heart attack patients admitted to Michigan hospitals could be significantly reduced if a statewide public smoking ban were implemented, according to a Henry Ford Hospital study.

11 Nov 2008

Increased heart attack deaths in NYC ambulance diversions confirmed in new research

Ambulance diversions from nearby, crowded New York emergency rooms to more distant emergency departments are associated with increased deaths among patients suffering from heart attacks, according to a paper presented at a meeting of the Institute for Operations Research and the Management Sciences (INFORMS®).

11 Nov 2008

Secondary prevention program may reduce risks after heart attack

An intensive, comprehensive, long-term secondary prevention program lasting up to three years after cardiac rehabilitation appears to reduce the risk of a second non-fatal heart attack and other cardiovascular events, according to a report in the November 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.

11 Nov 2008

New performance measures on performance measurement and reperfusion therapy

The ACC/AHA 2008 Task Force on Performance Measures' Statement on Performance Measurement and Reperfusion Therapy will webpost on Monday, November 10 at 2 pm ET.

11 Nov 2008

Data expands the clinical utility of deCODE tests for heart attack, atrial fibrillation and stroke

Several presentations by deCODE genetics scientists and independent researchers at the American Heart Association Scientific Sessions 2008 being held at the New Orleans Convention Center from November 8 to12 are expected to expand upon the clinical utility of evaluating individual risk of heart attack, or atrial fibrillation and stroke, respectively, by measuring the genetic markers that are the basis of the deCODE MI and deCODE AF tests.

11 Nov 2008

Initiative by world-recognized specialists in heart disease and diabetes to reduce residual vascular risk

Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes.

10 Nov 2008

Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes

Low-dose aspirin as primary prevention did not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type 2 diabetes, according to a new study in JAMA.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Advances in use of stem cells for tissue regeneration

A major issue in the development of regenerative medicine is the cell sources used to rebuild damaged tissues.

7 Nov 2008

For African Americans with hypertensive nephrosclerosis, end stage renal disease risks exceed risk of death from heart disease

For most patients with chronic kidney disease (CKD), the risk of experiencing a cardiovascular related death is greater than the risk of progressing to end-stage renal disease (ESRD).

7 Nov 2008

ERSD, heart disease and African-Americans with hypertensive nephrosclerosis

For most patients with chronic kidney disease (CKD), the risk of experiencing a cardiovascular related death is greater than the risk of progressing to end-stage renal disease (ESRD).

7 Nov 2008

Risk of sudden cardiac death greater in 30 days following heart attack

The risk of sudden cardiac death following a heart attack has declined significantly in the past 30 years, although patients appear to be at elevated risk for sudden cardiac death for the first month after having a heart attack, after which time their risk decreases unless they develop heart failure, according to a study in the November 5 issue of JAMA.

5 Nov 2008

Experts available to comment on risk of sudden cardiac death in 30 days following a heart attack

A new study in the November 5th 2008 issue of JAMA finds that during the first month after a heart attack, patients may have an increased risk for sudden cardiac death.

5 Nov 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008

Adjusting the clocks to summer time affects risk of heart attack

Adjusting the clocks to summer time on the last Sunday in March increases the risk of myocardial infarction in the following week. In return, putting the clocks back in the autumn reduces the risk, albeit to a lesser extent. This according to a new Swedish study published in the prestigious New England Journal of Medicine.

30 Oct 2008

Developing depression after a heart attack increases one’s risk of death or readmission

Science has found many links between depression and other serious medical illnesses, such as cancer, stroke, diabetes, and heart disease. For example, people who develop depression following a heart attack (myocardial infarction) or chest pain (angina) have an elevated risk of cardiac death or hospital readmission over the following year.

22 Oct 2008

Aires Pharmaceuticals signs license agreement with NIH

Aires Pharmaceuticals Inc. today announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions.

22 Oct 2008

Myocardial Infarction News and Research

Tailored anti-clotting medications reduce adverse effects after percutaneous coronary intervention

Timing is everything for some heart attack patients

Rivaroxaban shows promise in patients with acute coronary syndrome

Public smoking ban would reduce heart attack admissions

Increased heart attack deaths in NYC ambulance diversions confirmed in new research

Secondary prevention program may reduce risks after heart attack

New performance measures on performance measurement and reperfusion therapy

Data expands the clinical utility of deCODE tests for heart attack, atrial fibrillation and stroke

Initiative by world-recognized specialists in heart disease and diabetes to reduce residual vascular risk

Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

Advances in use of stem cells for tissue regeneration

For African Americans with hypertensive nephrosclerosis, end stage renal disease risks exceed risk of death from heart disease

ERSD, heart disease and African-Americans with hypertensive nephrosclerosis

Risk of sudden cardiac death greater in 30 days following heart attack

Experts available to comment on risk of sudden cardiac death in 30 days following a heart attack

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

Adjusting the clocks to summer time affects risk of heart attack

Developing depression after a heart attack increases one’s risk of death or readmission

Aires Pharmaceuticals signs license agreement with NIH

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News